About this survey, and you...
Thank you for taking this very short survey about clinical practice after the RESTART trial result. If you have already completed a survey about RESTART's results, you don't need to do so again. Otherwise please read on...
RESTART found that people with a history of occlusive vascular disease who survived intracerebral haemorrhage and started antiplatelet therapy (i.e. aspirin or clopidogrel) experienced fewer recurrences of brain hemorrhage than did similar people who continued to avoid antiplatelet drugs. The trial excluded all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy. The risk of recurrent intracerebral haemorrhage seemed too small to exceed the established benefits of antiplatelet therapy for secondary prevention. You can view a plain English summary, 2-3 minute video abstract, and links to the main paper in The Lancet and imaging sub-groups paper in The Lancet Neurology on the trials' website www.RESTARTtrial.org.
We are very keen to know what you think of these results...
Where do you work?
What is your role?
Were, or are, you an investigator in the RESTART trial
or SoSTART trial